La bromelina y su aplicación terapéutica antiinflamatoria en humanos: una revisión de alcance

• Areli ACOSTA FLORES ^[1] ; Angélica CASTELLANOS ESPINOSA ^[1] ; Andrea MARTÍNEZ RODRÍGUEZ ; Erick RAMÍREZ LÓPEZ ^[1] ; María Alejandra SÁNCHEZ PEÑA ^[1] ; Daniel LÓPEZ CAMARILLO ^[1] ; Adbel Zaid MARTÍNEZ BÁEZ ^[1]
  1. [1] Universidad Autónoma de Nuevo León

     Universidad Autónoma de Nuevo León

     México

     
• Localización: Nutrición clínica y dietética hospitalaria, ISSN 0211-6057, Vol. 43, Nº. 2, 2023, págs. 115-122
• Idioma: español
• Títulos paralelos:
  • Bromelain and its anti-inflammatory therapeutic application in humans: a scope review
• Enlaces
  • Texto completo
• Resumen
  • español

    La piña es el nombre común de Ananas comosus Merr (syns. A. sativus, Ananassa sativa, Bromelia ananas, B. comosa), se ha utilizado a lo largo del tiempo como remedio para curar diferentes padecimientos.

    Estudios in-vivo e in-vitro han demostrado eficacia terapéutica antiinflamatoria por medio de la eliminación de moléculas de la superficie celular, disminución de niveles de plasmaquininas, inhibidor de prostaglandinas, citocinas proinflamatorias, además que aumenta la permeabilidad tisular mediante fibrinólisis y promueve la reabsorción del líquido de edema en la circulación sanguínea.

    En la presente revisión se recopilaron artículos sobre bromelina y su actividad antiinflamatoria en humanos, basado en los criterios para el reporte de revisiones de alcance: PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). Tiene como objetivo describir dosis terapéuticas que tengan un efecto antiinflamatorio en humanos, lo anterior favorecería en la disminución de estancia hospitalaria, sintomatología y costos en los tratamientos.

  • English

    Introduction: Bromelain is a mixture of cysteine proteases found in tissue obtained from pineapple, Ananas comosus Merr, belonging to the bromeliad family. In-vivo and in-vitro studies have shown anti-inflammatory therapeutic efficacy through the elimination of molecules from the cellsurface, a decrease in plasmakinin levels, a prostaglandin inhibitor, pro-inflammatory cytokines, in addition to increasing tissue permeability through fibrinolysis and promoting the reabsorption of edema fluid in the bloodstream.

    Objective: This review aims to analyze the available evidence on the application and anti-inflammatory therapeuticdosage in humans of bromelain.

    Material and methods: Articles with a period from 2010 to2023 on bromelain and its anti-inflammatory activity in humanswere collected, based on the PRISMA criteria. The bibliographicsearch was carried out in seven electronic databases: PubMed, Scopus, Springer Link, Ovid, Redalyc, Scielo and Wiley.

    Results: Six of the twelve articles selected to carry out thework show the potential of bromelain as a possible alternativeto anti-inflammatory treatment. These studies have reported significant differences reporting therapeutic effects betweenstudy groups with administration from 160 mg/d, 500mg/d,1000 mg/d, 1000 FIP and 3000 FIP respectively with different dosing schedules.

    Discussion: One of the main disadvantages observed inthe reviewed articles was that the methodology is very varied, which makes it difficult to compare them. At the moment, information on the use of bromelain in inflammation is scarce in its application in humans, compared to other nutraceuticals.

    Conclusion: The importance of the usefulness of bromelain as an anti-inflammatory agent lies in the treatment of inflammation. It is necessary to increase double-blind studieswith specific doses in humans that evaluate inflammatory markers in different pathological processes.